Relay Therapeutics, Inc. (NASDAQ:RLAY - Get Free Report) insider Peter Rahmer sold 4,508 shares of Relay Therapeutics stock in a transaction on Wednesday, August 26th. The shares were sold at an average price of $20.03, for a total value of $90,295.24. Following the completion of the transaction, the insider directly owned 223,657 shares of the company's stock, valued at $4,479,849.71. This represents a 1.98% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.
Peter Rahmer also recently made the following trade(s):
- On Tuesday, July 28th, Peter Rahmer sold 748 shares of Relay Therapeutics stock. The shares were sold at an average price of $18.61, for a total value of $13,920.28.
- On Tuesday, June 30th, Peter Rahmer sold 50,000 shares of Relay Therapeutics stock. The stock was sold at an average price of $19.09, for a total transaction of $954,500.00.
Relay Therapeutics Stock Down 3.3%
RLAY opened at $18.77 on Friday. The stock has a market capitalization of $4.11 billion, a price-to-earnings ratio of -11.96 and a beta of 1.69. Relay Therapeutics, Inc. has a twelve month low of $3.52 and a twelve month high of $21.27. The company has a 50-day simple moving average of $19.27 and a 200 day simple moving average of $14.74.
Relay Therapeutics (NASDAQ:RLAY - Get Free Report) last released its earnings results on Thursday, August 6th. The company reported ($0.41) EPS for the quarter, missing the consensus estimate of ($0.39) by ($0.02). The business had revenue of $0.35 million for the quarter, compared to analysts' expectations of $0.96 million. Sell-side analysts anticipate that Relay Therapeutics, Inc. will post -1.61 EPS for the current fiscal year.
Hedge Funds Weigh In On Relay Therapeutics
A number of institutional investors and hedge funds have recently bought and sold shares of RLAY. AQR Capital Management LLC boosted its stake in shares of Relay Therapeutics by 11.9% during the first quarter. AQR Capital Management LLC now owns 364,946 shares of the company's stock valued at $956,000 after purchasing an additional 38,812 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake in shares of Relay Therapeutics by 6.6% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 84,069 shares of the company's stock valued at $221,000 after buying an additional 5,238 shares during the period. Millennium Management LLC increased its stake in shares of Relay Therapeutics by 14.6% in the first quarter. Millennium Management LLC now owns 2,942,875 shares of the company's stock valued at $7,710,000 after buying an additional 374,491 shares during the period. Dynamic Technology Lab Private Ltd bought a new position in Relay Therapeutics in the 1st quarter valued at approximately $53,000. Finally, Woodline Partners LP boosted its position in Relay Therapeutics by 448.4% during the 1st quarter. Woodline Partners LP now owns 1,518,561 shares of the company's stock worth $3,979,000 after buying an additional 1,241,657 shares during the period. Institutional investors and hedge funds own 96.98% of the company's stock.
Analyst Ratings Changes
Several equities analysts have recently issued reports on RLAY shares. Citigroup reiterated a "market outperform" rating on shares of Relay Therapeutics in a research note on Monday, August 10th. Wall Street Zen downgraded Relay Therapeutics from a "hold" rating to a "sell" rating in a research report on Saturday, August 15th. JPMorgan Chase & Co. raised their price objective on Relay Therapeutics from $28.00 to $31.00 and gave the company an "overweight" rating in a research note on Friday, August 14th. Guggenheim reiterated a "buy" rating on shares of Relay Therapeutics in a research report on Friday, August 7th. Finally, UBS Group set a $26.00 target price on Relay Therapeutics in a research note on Tuesday, May 19th. Two research analysts have rated the stock with a Strong Buy rating, ten have assigned a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the company currently has an average rating of "Moderate Buy" and an average price target of $25.92.
View Our Latest Research Report on Relay Therapeutics
About Relay Therapeutics
(
Get Free Report)
Relay Therapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of precision therapies for oncology. Headquartered in Cambridge, Massachusetts, the company was founded in 2016 with the goal of targeting dynamic protein motion using an integrated scientific platform. Relay Therapeutics leverages computational modeling, structural biology, and experimental validation to identify small-molecule drug candidates that modulate the behavior of disease-associated proteins.
The company's core business activity centers on its proprietary drug-discovery engine, which combines high-performance computing—including molecular dynamics simulations—with advanced experimental techniques such as cryo-electron microscopy and biophysical screening.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
